Shan Huang, Ling Ren, Jessica A Beck, Tim E Phelps, Colleen Olkowski, Anita Ton, Jyoti Roy, Margaret E White, Stephen Adler, Karen Wong, Aswini Cherukuri, Xiang Zhang, Falguni Basuli, Peter L Choyke, Elaine M Jagoda, Amy K LeBlanc
Background: Osteosarcoma (OS) is an aggressive pediatric cancer with unmet therapeutic needs. Glutaminase 1 (GLS1) inhibition, alone and in combination with metformin, disrupts the bioenergetic demands of tumor progression and metastasis, showing promise for clinical translation. Materials and Methods: Three positron emission tomography (PET) clinical imaging agents, [18 F]fluoro-2-deoxy-2-D-glucose ([18 F]FDG), 3'-[18 F]fluoro-3'-deoxythymidine ([18 F]FLT), and (2S, 4R)-4-[18 F]fluoroglutamine ([18 F]GLN), were evaluated, using the MG63...
May 29, 2023: Cancer Biotherapy & Radiopharmaceuticals